Biotech Values

[exwannabe]

Does anybone know why BSRDavid diss'd INGN's last PR?

http://biz.yahoo.com/bw/070927/20070927005160.html?.v=1

A few weeks agoe INGN released a PR that seamed positive. There ADVEXIN drug places the P53 gene into cancer cells, and analysis from P2 trials showed that the responders were only those who had cancers with P53 mutations. Logically, this seams like a positive.

I see from the history of INGN that they release a plethorea of BS PRs. "Our new drug showed benifits amongst left handed patients".

Is David just saying any INGN PR is BS, or does he (or anyone) have a specific point against ADVXIN?

I do see the possibility that the data might imply ADVEXIN works only in Li-Fraumeni Syndrom cancers, but I can't find nearly enough data on the actual trial results to know if this is his point.

(Traveling with limited net connectivity, so maybe I just can't search as well as I should)